Advertisement

Topics

Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting

14:15 EDT 2 Jun 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Positive NEOD001 Phase 1/2 Results Further Support the Design of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial Increase in Best Response Rate to 60% in 15 Renal-Evaluable Patients Increase in Best Response Rate to 57% in 14 Card...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...